docetaxel + oxaliplatin + fluorouracil

This drug entry refers to a modified triplet chemotherapy regimen consisting of docetaxel, oxaliplatin, and fluorouracil (mDOF). It is currently being evaluated in a Phase II clinical trial led by the Sixth Affiliated Hospital, Sun Yat-sen University, specifically for patients with advanced gastric or gastroesophageal junction adenocarcinoma who also present with peritoneal carcinomatosis and inoperable malignant bowel obstruction. The regimen combines three distinct mechanisms of action: docetaxel stabilizes microtubules to prevent cell division, oxaliplatin induces DNA cross-linking to inhibit replication, and fluorouracil acts as an antimetabolite by inhibiting thymidylate synthase. This combination is designed to provide intensive systemic therapy for high-burden metastatic disease while managing severe complications like bowel obstruction.

Other names

modified triplet combination of docetaxel, oxaliplatin and fluorouracilmodified DOF